Zenas BioPharma, Inc. (ZBIO), on Monday announced positive results from the Phase 2 MoonStone trial of obexelimab in patients with relapsing multiple sclerosis (RMS).
The study met its primary endpoint, showing a 95% relative reduction in the cumulative number of new gadolinium (Gd)-enhancing T1 hyperintense lesions at weeks 8 and 12 compared with placebo.
The company said it expects to report 24-week data in the first quarter of 2026, including additional secondary and exploratory endpoints that may provide insight into obexelimab's potential impact on disability progression and guide further development in RMS.
Zenas also expects to report topline results from the Phase 3 INDIGO trial of obexelimab in IgG4-related disease (IgG4-RD), a chronic, immune-mediated fibroinflammatory condition, around year-end 2025. In addition, topline data from the Phase 2 SunStone trial in systemic lupus erythematosus (SLE) are anticipated in mid-2026, along with the 24-week results from the MoonStone trial expected in the first quarter of 2026.
Zenas BioPharma shares rose more than 6% in pre-market trading Monday, following Friday's close at $24.21.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.